9 2 • O U T PA T I E N T S U R G E R Y M A G A Z I N E • J u l y 2 0 1 8
• Omidria pass-through status. Omidria, the intracameral phenyle-
phrine/ketorolac injectable that helps maintain pupillary dilation
intraoperatively, is about to be very affordable once again. The drug
enjoyed 3 years of "pass-through" status, meaning that the cost was
fully refunded in hospitals and refunded 80% in ASCs, but that ended
on Dec. 31, 2017. This spring, though, Congress voted to give the drug
2 more years of pass-through status. Following a 9-month hiatus, that
new period begins October 1, 2018. The HCPCS code is C9447.
• Omidria will once again have pass-
through status come October.
